Objective:

To develop, manufacture, and commercialize LNZ100, a prescription eye drop for presbyopia, across Greater China.

Approach:

Key Findings:

• LNZ100 is designed to improve near vision without overstimulating the ciliary muscle.
• The drug was well tolerated with no serious treatment-related adverse events reported.
• Presbyopia prevalence in China reaches nearly 100% by age 52, with limited current treatment options.

Interpretation:

Limitations:

• No drug is currently approved for presbyopia in China.
• Current treatment options are limited to glasses and invasive surgery.

Conclusion:

Everest's transaction aims to expand its ophthalmology portfolio and strengthen business synergies.

Sources:

• PR Newswire
Attribution Notice

This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.